Jianmin Li

Dr. Jianmin Li

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2020 in Science
Verified
Journal Article
Open access
PDF file
XCXiangyang Chi
Xiangyang Chi
RYRenhong Yan
Renhong Yan
JZJUN ZHANG
JUN ZHANG
GZGuanying Zhang
Guanying Zhang
YZYuanyuan Zhang
Yuanyuan Zhang
WCWei Chen
Wei Chen
Hitting SARS-CoV-2 in a new spot: A key target for therapeutic antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the spike protein, a trimeric protein complex with each monomer comprising an S1 and an S2 domain that mediate binding to host cells and membrane fusion, respectively. In addition to the receptor binding domain (RBD), S1 has an N-terminal domain (NTD). In searching for neutralizing antibodies, there has been a focus on the RBD. Chi et al. isolated antibodies from 10 convalescent patients and identified an antibody that potently neutralizes the virus but does not bind the RBD. Cryo–electron microscopy revealed the epitope as the NTD. This NTD-targeting antibody may be useful to combine with RBD-targeting antibodies in therapeutic cocktails. Science , this issue p. 650

14 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SWShipo Wu
Shipo Wu
GZGongxun Zhong
Gongxun Zhong
JZJUN ZHANG
JUN ZHANG
LSLei Shuai
Lei Shuai
ZZZhang Zhang
Zhang Zhang
WCWei Chen
Wei Chen
The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.

15 November 2021 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
XZXinfan Zhang
Xinfan Zhang
SWShuhua Wu
Shuhua Wu
CGChong Guo
Chong Guo
KGKe Guo
Ke Guo
ZHZhongbo Hu
Zhongbo Hu
JLJianmin Li
Jianmin Li

13 August 2020 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
RLRui Liu
Rui Liu
SWShuhua Wu
Shuhua Wu
CGChong Guo
Chong Guo
ZHZhongbo Hu
Zhongbo Hu
JPJiangtao Peng
Jiangtao Peng
JLJianmin Li
Jianmin Li

18 September 2019 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
JPJiangtao Peng
Jiangtao Peng
SWShuhua Wu
Shuhua Wu
CGChong Guo
Chong Guo
KGKe Guo
Ke Guo
WZWeiguo Zhang
Weiguo Zhang
ZHZhongbo Hu
Zhongbo Hu

27 February 2020 in Viruses
Verified
Journal Article
Open access
PDF file
MHMeng Hao
Meng Hao
GZGuanying Zhang
Guanying Zhang
SZShengnan Zhang
Shengnan Zhang
ZCZhengshan Chen
Zhengshan Chen
XCXiangyang Chi
Xiangyang Chi
XXXianzhu Xia
Xianzhu Xia
The Rift Valley fever virus (RVFV) is an arthropod-borne virus that can not only cause severe disease in domestic animals but also in humans. However, the licensed vaccines or available therapeutics for humans do not exist. Here, we report two Gn-specific neutralizing antibodies (NAbs), isolated from a rhesus monkey immunized with recombinant human adenoviruses type 4 expressing Rift Valley fever virus Gn and Gc protein (rHAdV4-GnGcopt). The two NAbs were both able to protect host cells from RVFV infection. The interactions between NAbs and Gn were then characterized to demonstrate that these two NAbs might preclude RVFV glycoprotein rearrangement, hindering the exposure of fusion loops in Gc to endosomal membranes after the virus invades the host cell. The target region for the two NAbs is located in the Gn domain III, implying that Gn is a desired target for developing vaccines and neutralizing antibodies against RVFV.